No annual revenue total was found in Semnur Pharmaceuticals, Inc.'s SEC filings.
Semnur Pharmaceuticals, Inc. (SMNR) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income (TTM)
$-18.71M
+87.9% vs year-ago TTM
Operating cash flow (TTM)
$-10.63M
-189.9% vs year-ago TTM
Free cash flow
—
EPS (TTM)
$-0.08
Dividend per share
None
Shares outstanding
230.21M
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SMNR (OTC), SMNRW (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Palo Alto, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1913577
- Former names
- Denali Capital Acquisition Corp. (until Sep 23, 2025)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
|---|---|---|---|---|
| Operating income | -$160.4M | -$4.7M | — | — |
| Net income | -$160.4M | -$4.7M | $632,536 | -$419,390 |
| Diluted EPS | -$0.78 | — | — | — |
| Operating cash flow | -$5.9M | -$4.9M | -$632,783 | -$426,095 |
| Total assets | $1.3M | $6.7M | $50.7M | $86.3M |
| Total liabilities | $22.1M | $49.5M | $8.5M | $4.2M |
| Stockholders' equity | -$20.8M | -$42.8M | -$38.1M | -$3.3M |
| Cash and investments | $20,000 | — | $204,464 | $819,747 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Jul 7, 2026 | Jul 3, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 25, 2026 | Jun 25, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
| ARS | Annual report to shareholders | Apr 30, 2026 | Dec 31, 2025 |
All 221 Semnur Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.